AKAnna Kaarina Kukkonen

Anna Kaarina Kukkonen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Anna Kaarina Kukkonen has a total of 59 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Human milk antibodies to global pathogens reveal geographic and interindividual variations in IgA and IgG

    by Joseph J. Campo, Antti E. Seppo, Arlo Z. Randall, Jozelyn Pablo, Chris Hung, Andy Teng, Adam D. Shandling, Johnathon Truong, Amit Oberai, James Miller, et al.

    BACKGROUND: The use of high-throughput technologies has enabled rapid advancement in the knowledge of host immune responses to pathogens. Our objective was to compare the repertoire, protection, and maternal factors associated with human milk antibodies to infectious pathogens in different economic and geographic locations. METHODS: Using multipathogen protein microarrays, 878 milk and 94 paired serum samples collected from 695 women in 5 high and low-to-middle income countries (Bangladesh, Finland, Peru, Pakistan, and the United States) were assessed for specific IgA and IgG antibodies to 1,607 proteins from 30 enteric, respiratory, and bloodborne pathogens. RESULTS: The antibody coverage across enteric and respiratory pathogens was highest in Bangladeshi and Pakistani cohorts and lowest in the U.S. and Finland. While some pathogens induced a dominant IgA response ( Campylobacter , Klebsiella, Acinetobacter , Cryptosporidium, and pertussis), others elicited both IgA and IgG antibodies in milk and serum, possibly related to the invasiveness of the infection ( Shigella, enteropathogenic E . coli “EPEC” , Streptococcus pneumoniae, Staphylococcus aureus, and Group B Streptococcus) . Besides the differences between economic regions and decreases in concentrations over time, human milk IgA and IgG antibody concentrations were lower in mothers with high BMI and higher parity, respectively. In Bangladeshi infants, a higher specific IgA concentration in human milk was associated with delayed time to rotavirus infection, implying protective properties of antirotavirus antibodies, whereas a higher IgA antibody concentration was associated with greater incidence of Campylobacter infection. CONCLUSION: This comprehensive assessment of human milk antibody profiles may be used to guide the development of passive protection strategies against infant morbidity and mortality. FUNDING: Bill and Melinda Gates Foundation grant OPP1172222 (to KMJ); Bill and Melinda Gates Foundation grant OPP1066764 funded the MDIG trial (to DER); University of Rochester CTSI and Environmental Health Sciences Center funded the Rochester Lifestyle study (to RJL); and R01 AI043596 funded PROVIDE (to WAP).


  • Open Access

    Probiotic supplementation restores normal microbiota composition and function in antibiotic-treated and in caesarean-born infants

    by Katri Korpela, Anne Salonen, Outi Vepsäläinen, Marjo Suomalainen, Carolin Kolmeder, Markku Varjosalo, Sini Miettinen, Kaarina Kukkonen, Erkki Savilahti, Mikael Kuitunen, et al.

    Infants born by caesarean section or receiving antibiotics are at increased risk of developing metabolic, inflammatory and immunological diseases, potentially due to disruption of normal gut microbiota at a critical developmental time window. We investigated whether probiotic supplementation could ameliorate the effects of antibiotic use or caesarean birth on infant microbiota in a double blind, placebo-controlled randomized clinical trial. Mothers were given a multispecies probiotic, consisting of Bifidobacterium breve Bb99 (Bp99 2 × 108 cfu) Propionibacterium freundenreichii subsp. shermanii JS (2 × 109cfu), Lactobacillus rhamnosus Lc705 (5 × 109 cfu) and Lactobacillus rhamnosus GG (5 × 109 cfu) (N = 168 breastfed and 31 formula-fed), or placebo supplement (N = 201 breastfed and 22 formula-fed) during pregnancy, and the infants were given the same supplement. Faecal samples of the infants were collected at 3 months and analyzed using taxonomic, metagenomic and metaproteomic approaches. The probiotic supplement had a strong overall impact on the microbiota composition, but the effect depended on the infant’s diet. Only breastfed infants showed the expected increase in bifidobacteria and reduction in Proteobacteria and Clostridia. In the placebo group, both birth mode and antibiotic use were significantly associated with altered microbiota composition and function, particularly reduced Bifidobacterium abundance. In the probiotic group, the effects of antibiotics and birth mode were either completely eliminated or reduced. The results indicate that it is possible to correct undesired changes in microbiota composition and function caused by antibiotic treatments or caesarean birth by supplementing infants with a probiotic mixture together with at least partial breastfeeding. clinicaltrials.gov NCT00298337 . Registered March 2, 2006.


  • Open Access

    Childhood BMI in relation to microbiota in infancy and lifetime antibiotic use

    by K. Korpela, M. A. C. Zijlmans, M. Kuitunen, K. Kukkonen, E. Savilahti, A. Salonen, C. de Weerth, W. M. de Vos

    Children with high body mass index (BMI) at preschool age are at risk of developing obesity. Early identification of factors that increase the risk of excessive weight gain could help direct preventive actions. The intestinal microbiota and antibiotic use have been identified as potential modulators of early metabolic programming and weight development. To test if the early microbiota composition is associated with later BMI, and if antibiotic use modifies this association, we analysed the faecal microbiota composition at 3 months and the BMI at 5–6 years in two cohorts of healthy children born vaginally at term in the Netherlands (N = 87) and Finland (N = 75). We obtained lifetime antibiotic use records and measured weight and height of all children. The relative abundance of streptococci was positively and the relative abundance of bifidobacteria negatively associated with the BMI outcome. The association was especially strong among children with a history of antibiotic use. Bacteroides relative abundance was associated with BMI only in the children with minimal lifetime antibiotic exposure. The intestinal microbiota of infants are predictive of later BMI and may serve as an early indicator of obesity risk. Bifidobacteria and streptococci, which are indicators of microbiota maturation in infants, are likely candidates for metabolic programming of infants, and their influence on BMI appears to depend on later antibiotic use.


  • Double‐blind placebo‐controlled challenge showed that peanut oral immunotherapy was effective for severe allergy without negative effects on airway inflammation

    by Anna Kaarina Kukkonen, Riikka Uotila, Leo Pekka Malmberg, Anna Susanna Pelkonen, Mika Juhani Mäkelä

    Aim: This study examined the efficacy and the safety of peanut oral immunotherapy (OIT).Methods: We recruited 60 patients aged six years to 18 years who had a moderate‐to‐severe reaction to a double‐blind placebo‐controlled peanut challenge: 39 received OIT during an eight‐month build‐up phase and maintenance phase and 21 controls avoided peanuts. We measured specific immunoglobulin E and G4 (IgE and IgG4) to peanuts and to Ara h 1, 2, 3, 8 and 9 and monitored adverse events, bronchial hyper‐responsiveness (BHR) to methacholine and fractional concentrations of exhaled nitric oxide (FeNO). The median follow‐up period was 30 months.Results: Most (85%) of the OIT patients passed the build‐up phase and 67% tolerated 5 g of peanuts during the post‐treatment challenge. No controls were desensitised, with a risk ratio of 29 and 95% confidence interval of 1.9–455. During OIT, IgE to peanut, Ara h 1, 2 and 3 decreased and IgG4 increased. Consuming peanuts had no harmful effects on BHR or FeNO. The annual incidence rate of emergency visits during the follow‐up period was 11% or 3.0 per 10 000 patient‐days.Conclusion: Peanut OIT was efficacious in severe allergies without negative effects on airway inflammation, but unpredictable long‐term reactions might occur.


  • Ara h 2 and Ara 6 are the best predictors of severe peanut allergy: a double‐blind placebo‐controlled study

    by A. K. Kukkonen, A. S. Pelkonen, S. Mäkinen‐Kiljunen, H. Voutilainen, M. J. Mäkelä

    Background: Component‐resolved diagnostics offers a modern tool in peanut allergy, but studies applying consistently double‐blind placebo‐controlled challenges are lacking. We aimed to optimize diagnostics for moderate‐to‐severe peanut allergy in a birch‐endemic region and to create an oral‐peanut challenge with its allergen activity characterized.Methods: We performed double‐blind placebo‐controlled peanut challenges for a referred sample of 6‐ to 18‐year‐olds with peanut sensitization or a high suspicion of peanut allergy, including anaphylaxis. We measured specific IgE (sIgE) to Ara h 1, 2, 3, 6, 8, and 9. Testing of allergen activity of the challenge products was by IgE microarray inhibition.Results: Of the 102 patients, 69 were challenge positive: 25 (36%) had severe, 36 (52%) moderate, and 8 (12%) mild symptoms; 38 (37%) received adrenalin. SIgE to Ara h 6 AUC 0.98 (95%CI, 0.96–1.00) was the best marker of moderate‐to‐severe allergy. When sIgE to Ara h 2 and Ara h 6 was measured together, all (100%) severe reactions at low doses were successfully diagnosable. SIgE to Ara h 8 had no diagnostic value, AUC 0.42 (95%CI, 0.30–0.52). Both nonroasted and roasted peanut inhibited 100% of IgE binding to Ara h 1, 2, 3, and 6. Nonroasted peanut inhibited 87% of IgE binding to Ara h 8, roasted inhibited 30%. The products lacked Ara h 9 activity.Conclusion: Co‐sensitization to Ara h 2 and Ara h 6 was associated with severe reactions distinguishing severe allergy from mild symptoms. SIgE to Ara h 8 added no diagnostic value. Component‐resolved diagnostics reduce the need for oral challenges in peanut allergy.


  • Turnip rapeseed does not worsen atopic eczema in most sensitized children

    by Anna Kaarina Kukkonen, Anna Pelkonen, Soili Mäkinen‐Kiljunen, Mikael Kuitunen, Mika J. Mäkelä


  • Ovalbumin‐specific immunoglobulins A and G levels at age 2 years are associated with the occurrence of atopic disorders

    by A. K. Kukkonen, E. M. Savilahti, T. Haahtela, M. Kuitunen

    Summary: Background Humoral responses to food antigens may reflect the propensity of a child's immune system to develop tolerance to innocuous antigens. Early nutrition as well as probiotics may influence these immunological responses. Objective To study the association of humoral responses to early food antigens with the administration of prebiotics and probiotics, with the occurrence of allergy, and with the length of exclusive breastfeeding. Methods In a randomized double‐blind allergy prevention trial in high‐risk children, 1018 mothers took probiotics or placebo from the 36th week of gestation, and their newborn infants received probiotics and prebiotics or placebo during 6 months. At 2 and 5 years, we evaluated the cumulative incidence of allergic diseases (food allergy, eczema, asthma, rhinitis) and sensitization (skin prick test ⩾3 mm or serum antigen‐specific IgE>0.7 kU/L). In 688 infants at age 2, we measured in sera‐specific IgA, IgG, IgG1, and IgG4 antibody levels to cow's milk (CM), α‐casein (CAS), β‐lactoglobulin (BLG), and ovalbumin (OVA) with ELISA, and specific IgE levels to CM and hen's egg with UniCap. Results Probiotic treatment (n=342) compared with placebo (n=346) showed no effect on serum food‐specific IgA, IgG, IgG1, or IgG4 concentrations at age 2. Atopic children had higher OVA‐IgA (PP=0.001), OVA‐IgG1 (PPPPP=0.003). Conclusion and Clinical Relevance Allergy was associated with more intense IgA and IgG responses to OVA. Breastfeeding depressed humoral responses, whereas prebiotics and probiotics supplementation showed no immunomodulatory effect. The effect of probiotics on allergies is not mediated through food‐specific antibody responses. Furthermore, OVA‐specific IgA and IgG antibodies may help in assessing the risk for atopy. [Trial registration: Clinicaltrials.gov NCT00298337] Cite this as: A. K. Kukkonen, E. M. Savilahti, T. Haahtela, E. Savilahti and M. Kuitunen, Clinical & Experimental Allergy, 2011 (41) 1414–1421.


  • Airway inflammation in probiotic‐treated children at 5 years

    by Anna K. Kukkonen, Mikael Kuitunen, Erkki Savilahti, Anna Pelkonen, Pekka Malmberg, Mika Mäkelä

    To cite this article: Kukkonen AK, Kuitunen M, Savilahti E, Pelkonen A, Malmberg P, Mäkelä M. Airway inflammation in probiotic‐treated children at 5 years. Pediatr Allergy and Immunol 2011; 22: 249–251.Early treatment of new‐born high‐risk children with certain probiotic strains has reduced the risk of atopic eczema. Whether probiotics reduce risk for airway inflammation in long term is not known. We aimed at studying the effect of probiotic treatment during the six first months of life on airway inflammation at age 5 yr. In a randomized double‐blind allergy prevention trial between 2000 and 2007 in Helsinki, Finland, we gave a probiotic combination, plus pre‐biotics, or placebo, to 1018 children during 6 months from birth. At age 5, we measured exhaled nitric oxide (FENO) in a randomized sub‐population of 160 children. Allergic diseases and IgE‐sensitization were assessed in all infants. FENO did not differ between probiotic and placebo groups, median (interquartile range, IQR) 5.45 (4.3–7.3) vs. 5.70 (3.9–6.8) ppb, p = 0.22. FENO was elevated among those suffering from asthma during the first 5 yr than in healthy non‐sensitized children (p = 0.009). FENO correlated positively with serum total and allergen‐specific IgE concentrations. Early intervention with probiotics and pre‐biotics does not affect airway inflammation later in childhood.


  • High intestinal IgA associates with reduced risk of IgE‐associated allergic diseases

    by Kaarina Kukkonen, Mikael Kuitunen, Tari Haahtela, Riitta Korpela, Tuija Poussa, Erkki Savilahti

    Kukkonen K, Kuitunen M, Haahtela T, Korpela R, Poussa T, Savilahti E. High intestinal IgA associates with reduced risk of IgE‐associated allergic diseases. Pediatr Allergy Immunol 2010: 21: 67–73. © 2009 John Wiley & Sons A/SDevelopment of oral tolerance and its stimulation by probiotics are still incomprehensible. Microbial stimulation of the gut may induce a subtle inflammation and induce secretion of mucosal IgA, which participates in antigen elimination. In a cohort of allergy‐prone infants receiving probiotics and prebiotics or placebo we studied intestinal IgA and inflammation in the development of eczema, food allergy, asthma, and rhinitis (allergic diseases). We performed a nested unmatched case–control study of 237 infants participating in a randomized double‐blind placebo‐controlled allergy‐prevention trial using a combination of four probiotic strains pre‐natally and during 6 months form birth. We measured faecal IgA, α1‐antitrypsin (α1‐AT), tumour necrosis factor‐alpha (TNF‐α), and calprotectin at the age of 3 and 6 months. By age 2 yr, 124 infants had developed allergic disease or IgE‐sensitization (cases) and 113 had not (controls). In infants with high faecal IgA concentration at the age of 6 months, the risk of having any allergic disease before the age of 2 yr tended to reduce [odds ratio (OR: 0.52)] and the risk for any IgE‐associated (atopic) disease reduced significantly (OR: 0.49). High faecal calprotectin at the age of 6 months associated also with lower risk for IgE‐associated diseases up to age 2 yr (OR: 0.49). All faecal inflammation markers (α1‐AT, TNF‐α, and calprotectin) correlated positively with faecal IgA (p < 0.001). Probiotics tended to augment faecal IgA (p = 0.085) and significantly increased faecal α1‐AT (p = 0.001). High intestinal IgA in early life associates with minimal intestinal inflammation and indicates reduced risk for IgE‐associated allergic diseases.